Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.

Antimicrobial agents and chemotherapy - 1 Nov 2005

Nishikawa Masao, Takashima Katsunori, Nishi Toshiya, Furuta Rika A, Kanzaki Naoyuki, Yamamoto Yoshio, Fujisawa Jun-Ichi

Abstract excerpt

G protein-coupled receptor CCR5 is the main coreceptor for macrophage-tropic human immunodeficiency virus type 1 (HIV-1), and various small-molecule CCR5 antagonists are being developed to treat HIV-1 infection. It has been reported that such CCR5 antagonists, including TAK-779, bind to a putative binding pocket formed by transmembrane domains (TMs) 1, 2, 3 and 7 of CCR5, indicating the importance of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding Sites

Share to CCR5 Receptor Antagonists

Share to Piperidines

Share to Quaternary Ammonium Compounds

Share to Receptors, CCR5

Source

Open in PubMed Open full text

Identifiers

PMID: 16251315
DOI: 10.1128/AAC.49.11.4708-4715.2005
PMCID: PMC1280122

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.PMID 16251315Read ↗

Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 EntrySemantic proximity Read ↗

The Expanding Therapeutic Perspective of CCR5 BlockadeSemantic proximity Read ↗

Small-Molecule Antagonists of CCR5 and CXCR4: A Promising New Class of Anti-HIV-1 DrugsSemantic proximity Read ↗

HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.Semantic proximity Read ↗

Structural and Molecular Interactions of CCR5 Inhibitors with CCR5Semantic proximity Read ↗

Interaction of small molecule inhibitors of HIV-1 entry with CCR5Semantic proximity Read ↗

NMR analyses of the interaction between CCR5 and its ligand using functional reconstitution of CCR5 in lipid bilayers.Semantic proximity Read ↗

The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.Semantic proximity Read ↗

Isolation and Characterization of Human Immunodeficiency Virus Type 1 Resistant to the Small-Molecule CCR5 Antagonist TAK-652Semantic proximity Read ↗

Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor.Semantic proximity Read ↗

A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.Semantic proximity Read ↗

Mechanistic Insights into PRRSV Inhibition through CD163–SRCR5 Blockade by PRRSV/CD163-IN-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.